RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Aims: The purpose of this study is to compare the effects, good and/or bad, of two standard treatments for head and neck cancer: radiation therapy plus the drug cisplatin or radiation therapy plus the drug cetuximab. The two treatments may be comparable in treating head and neck cancer, but radiation and cetuximab may result in less severe side effects. This study is being done in patients whose head and neck cancer was caused by Human Papillomavirus Virus (HPV). Some studies have found that patients with HPV-positive oropharynx cancer have a better response to treatment and live longer. Thus, this study aims to see if treatment with radiation plus cetuximab has less side effects and is as effective as radiation plus cisplatin.
Diagnosis: HPV-Associated Oropharynx Cancer
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH12-288
Sponsor: Radiation Therapy Oncology Group
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

HCN Tissue Bank: Tissue/Body Fluid Procurement and Clinical Data Collection for Patients with Malignancies of the Head and Neck Area and/or Pre-Malignant Changes
Aims: The purpose of this study is to collect tissue, blood, saliva, and/or clinical data (information about your treatment) from patients wtih a cancer in the head and neck area (or pre-malignant lesions) for research purposes. Certain genetic and biochemical changes are believed to lead to the development of head and neck cancer. Scientists are attempting to discover and understand the function of these changes. In the future, improved understanding of these changes may help us to better detect head and neck cancers and offer improved treatments.
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH13-276
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

UC09-266-B: Randomied Double-Blind Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and aneck (SCCHN)
Aims: This research is being done, because even after surgery and radiation therapy most people with SCCHN have their cancer come back within 5 years. The safety of this drug will also be studied, as well as the drug's effect on different cells in the body.
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH14-190
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

RTOG-1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell cancer of the Head and Neck
Aims: The purpose of the this part of this study is to find out what effects, good and/or bad, one of the following treatments has on you and your cancer. In this part of the study, you will receive one of the following treatments: • Standard treatment: radiation therapy and cisplatin • Experimental treatment: radiation therapy and docetaxel • Experimental treatment: radiation therapy, docetaxel, and cetuximab.
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH15-004
Sponsor: Radiation Therapy Oncology Group
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

AstraZeneca D4193C0001: A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell carcinoma of the Head and Neck (SCCHN)
Aims: This study is being carried out to see if an experimental anti-cancer drug called MEDI4736 (study drug) is effective in treating the type of cancer that you have. MEDI4836 is an antibody that has been made in the laboratory that may boost the ability of the immune system to detect and fight cancer.
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH14-364
Sponsor: AstraZeneca
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes
× Alternate Text